November 1, 2022
Capital and Business Alliance with GlyTech, Inc.
Tokyo, November 1, 2022 – KH Neochem Co., Ltd. (TSE: 4189, President and CEO: Michio Takahashi,“KH Neochem”) announced its capital participation in GlyTech, Inc. (“GlyTech”) by subscribing to athird-party allotment of new shares in October 2022.
Glycans, called the third chain of life for their function in vivo similar to nucleic acids and proteins,are known for their involvement in various biological phenomena such as cellular differentiation,
metabolism, immune response, cancer metastasis, viral infection, aging, and transmission ofinformation via cranial nerves. While research and development is being actively conducted in thelife science field such as the development of new drugs, the organic synthesis of glycans is difficult
due to their structural diversity. The mass production and stable supply of glycans are issues for thefurther advancement and promotion of scientific and industrial use.

GlyTech is a start-up withglycan mass production technologies and glycan modification technologies capable of conjugation ofglycans to proteins and peptides that are active ingredients in biopharmaceuticals. Utilizing theseplatform technologies, GlyTech provides drug discovery support in the form of contract research on
new drug candidate substances and the sale of glycans to pharmaceutical companies, chemical
manufacturers, universities, and research institutions in Japan and overseas.
KH Neochem has designated “Environment, Healthcare, Electronics” as its strategic domains forthe realization of VISION 2030, and has aimed to create new businesses. In the healthcare domain,
KH Neochem has focused on the potential of glycans, and has developed proprietary glycans andmanufacturing technologies. The strengthening of the relationship through this investment, aswell as the joint research on glycan manufacturing currently underway with GlyTech, will serve toaccelerate activities working towards the mass production and stable supply of various types ofglycans.

If glycans that show individual difference in vivo expression could be mass produced, thiswould promote the development of personalized medicine tailored to each individual such as
biopharmaceuticals and diagnostic drugs for cancer and lifestyle diseases, which is anticipated tolead to a significant improvement in individual quality of life. KH Neochem aims to further
contribute to enriching the lives of people around the world through the development oftechnologies such as the manufacturing of high-purity glycans.
This is KH Neochem’s second investment in a start-up, following its first investment in April of thisyear.
KH Neochem will continue to work on the creation of new business by actively utilizing open
innovation that deepens collaborative creation with outside parties to resolve social issues.

1/2

[About GlyTech]
Address:

Kyoto

Date of establishment:

April 2, 2012

President & CEO:Mr. Hiroaki Asai

Business description:

Supporting the development of innovative and improved medicines, suchas biopharmaceuticals based on the glycan production and chemical
glycosylation technologies.

URL:

https://www.glytech-inc.com■ Contact information for this matter
Public Relations
KH Neochem Co., Ltd.
kouhou@khneochem.co.jp###2/2